APPENDIX B.

Risk of Hospitalization in Sensitivity Analyses Among Propensity Score-Matched Patients

	Warfarin vs. Apixaban		Dabigatran vs. Apixaban		Rivaroxaban vs. Apixaban
Dosing form	n = 41,606	P Valuea	n = 30,836	P Valuea	n = 41,608	P Valuea
All-cause hospitalization
Standard doseb	1.36 (1.29-1.43)	< 0.001	1.16 (1.10-1.24)	0.229	1.23 (1.17-1.30)	0.792
Low doseb	1.17 (1.08-1.26)		1.25 (1.14-1.37)		1.25 (1.17-1.34)
Stroke/SE
Standard dose	2.92 (2.07-4.13)	0.063	2.32 (1.52-3.53)	0.967	1.57 (1.07-2.31)	0.576
Low dose	1.69 (1.07-2.68)		2.28 (0.99-3.96)		1.85 (1.21-2.82)
Major bleeding
Standard dose	1.89 (1.60-2.24)	0.586	1.45 (1.18-1.78)	0.502	2.07 (1.75-2.45)	0.554
Low dose	2.04 (1.64-2.55)		1.64 (1.40-2.12)		2.25 (1.83-2.76)
Censoring at 6 months	n = 41,606	P Value	n = 30,836	P Value	n = 41,608	P Value
All-cause hospitalization	1.37 (1.30-1.43)	< 0.001	1.20 (1.13-1.27)	< 0.001	1.32 (1.26-1.38)	< 0.001
Stroke/SE	2.39 (1.78-3.22)	< 0.001	2.12 (1.49-3.02)	< 0.001	1.71 (1.25-2.34)	< 0.001
Major bleeding	1.91 (1.65-2.22)	< 0.001	1.44 (1.19-1.74)	< 0.001	2.09 (1.81-2.42)	< 0.001
At least 30-day follow-up	n = 41,576	P Value	n = 30,824	P Value	n = 41,539	P Value
All-cause hospitalization	1.30 (1.25-1.36)	< 0.001	1.15 (1.09-1.21)	< 0.001	1.23 (1.18-1.28)	< 0.001
Stroke/SE	2.47 (1.87-3.26)	< 0.001	2.16 (1.52-3.05)	< 0.001	1.71 (1.28-2.29)	< 0.001
Major bleeding	1.93 (1.69-2.22)	< 0.001	1.47 (1.24-1.75)	< 0.001	2.15 (1.88-2.45)	< 0.001

Note: In the sensitivity analysis of dosing forms, standard-dose and low-dose dabigatran and rivaroxaban were compared with apixaban patients with the same dose.

^aP value is for interaction in the dosing form sensitivity analysis.

^bStandard dose: 5 mg twice a day apixaban, 150 mg twice a day dabigatran, 20 mg every day rivaroxaban; low dose: 2.5 mg twice a day apixaban, 75 mg twice a day dabigatran, 10 mg or 15 mg every day rivaroxaban.

SE = systemic embolism.